What Researchers Did
Researchers retrospectively analyzed 25 patients with stage IV metastatic pancreatic cancer treated at a Turkish center with a combined protocol of metabolically supported chemotherapy, ketogenic diet, hyperthermia, and HBOT.
What They Found
Median overall survival was 15.8 months and median progression-free survival was 12.9 months -- notably better than historical benchmarks of roughly 11 months for standard chemotherapy alone for this stage. No patient characteristics independently predicted survival.
What This Means for Canadian Patients
Stage IV pancreatic cancer has very poor outcomes. This study suggests combining HBOT with metabolic therapy may improve survival compared to chemotherapy alone. Canadian oncologists researching integrative cancer approaches may find this protocol worthy of controlled trial investigation.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This was a small retrospective study of 25 patients with no control arm; multiple interventions were combined, making it impossible to determine the specific contribution of HBOT.